90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R ... PipelineReview.com (press release) VANCOUVER, Canada I June 10, 2013 I Immunomedics, Inc. (IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, ... |
